CALL: (661) 257-8400

IPL FotoFacials

Correct sun damage on the face, neck, and chest with IPL FotoFacial.

CALL NOW!

Best for Treating:

Redness

Facial Capillaries

Brown
Spots

Sun
Damage

We all enjoy the California sunshine, but our skin unfortunately pays the price.

The majority of us suffer from uneven pigmentation, especially on our face, neck, and chest. Brown spots, red spots, broken capillaries and Rosacea can be a daily struggle. Makeup can help, but it only masks the problem. Most of us have been told that freckles, sun spots, and redness are characteristics we simply have to learn to live with. But what if there was a treatment that could wipe the slate clean?

Intense Pulsed Light (IPL) FotoFacial is a noninvasive laser light treatment highly effective in treating skin pigmentation woes without pain or downtime.

A high-intensity pulse of visible light is emitted to target hyperactive melanin-producing cell beneath the skin’s surface. The light is converted to heat energy which breaks up uneven pigmentation to reveal more radiant and even skin. Results continue to improve over time and patients can expect to see their best results 3 months after their last treatment.

Before

After

Before

After

“WOW. It's honestly been 20 years since I saw my skin looking this even. I look like me – but better. I don't even need foundation anymore.”
- AT

Dr. Ingber, M.D.

Dermacure is an aesthetic medical office owned and operated by Craig Ingber, MD a board certified Facial Plastic Surgeon.

Dr. Ingber is a clinical instructor of surgery at UCLA Medical School and performs all injections upon request. He is a top 1% injector of Botox and Juvederm in the nation and is the #1 physician injector in Santa Clarita Valley.

LEARN MORE ABOUT DR. INGBER

A flawless, even complexion awaits.

Correct sun damage on the face, neck, and chest with IPL FotoFacial.

Read More

KYBELLA® (deoxycholic acid) injection 10 mg/mL Important Information

INDICATION
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS 
KYBELLA® is contraindicated in the presence of infection at the injection sites.

WARNINGS AND PRECAUTIONS
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.

Injection Site Alopecia
Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Injection Site Ulceration and Necrosis
Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.

ADVERSE REACTIONS
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see KYBELLA® full Prescribing Information.

*Individual results may vary.
Call Us Today! 661-257-8400

A flawless, even complexion awaits.

Correct sun damage on the face, neck, and chest with IPL FotoFacial.

Read More

KYBELLA® (deoxycholic acid) injection 10 mg/mL Important Information

INDICATION
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.

The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS 
KYBELLA® is contraindicated in the presence of infection at the injection sites.

WARNINGS AND PRECAUTIONS
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.

Dysphagia
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.

Injection-Site Hematoma/Bruising
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.

Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.

Injection Site Alopecia
Cases of injection site alopecia have been reported with administration of KYBELLA®. Onset and duration may vary among individuals and may persist. Consider withholding subsequent treatments until resolution.

Injection Site Ulceration and Necrosis
Injections that are too superficial into the dermis may result in skin ulceration and necrosis. Cases of injection site ulceration and necrosis have been reported with administration of KYBELLA®. Do not administer KYBELLA® into affected area until complete resolution.

ADVERSE REACTIONS
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.

Please see KYBELLA® full Prescribing Information.

*Individual results may vary.
Call Us Today! 661-257-8400

I'm Interested!

Please contact me with more information on this procedure.

©2018 DermaCure Valencia | Web Design by Small Dog Creative